A carregar...
Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study
OBJECTIVE: To evaluate the safety and efficacy of cladribine tablets in patients still experiencing active relapsing MS despite interferon (IFN)-β treatment. METHODS: A 96-week phase II study, randomizing patients treated with IFN-β to cladribine tablets 3.5 mg/kg/IFN-β or placebo/IFN-β. Patients we...
Na minha lista:
| Publicado no: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6047834/ https://ncbi.nlm.nih.gov/pubmed/30027104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000477 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|